07:00 , Jul 19, 2010 |  BioCentury  |  Finance

Rationalizing DeveloGen

A total of $61.1 million in venture money went into DeveloGen AG in its three financing rounds from 1998-2004, but Evotec AG (Xetra:EVT) will get the metabolic and endocrine company for no more than €14...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Ebb & Flow

Amgen has shed $61 billion, or 58% of its market cap, over the last three and a half years and last week found itself slipping into third place among top tier biotechs, giving up the...
08:00 , Feb 25, 2008 |  BioCentury  |  Finance

Ebb & Flow

Encysive (NASDAQ:ENCY) has never disclosed exactly what the FDA doesn't like about the company's Phase III data on Thelin sitaxsentan, which has received three FDA approvable letters for pulmonary arterial hypertension (PAH) despite already being...
08:00 , Dec 10, 2007 |  BioCentury  |  Finance

Ebb & Flow

Genentech shares hit their lowest level since early 2005 last week, shedding $7.76 (10%) to reach $68.49 and lopping off more than $8 billion of the company's market cap to $72 billion. The dive came...
07:00 , Mar 12, 2007 |  BioCentury  |  Finance

Too much money

In 2002, MPM Capital closed what was the largest-ever dedicated healthcare fund. At $940 million, BioVentures III was intended to allow the firm to put its capital to work in $50-$100 million chunks as part...
01:20 , Mar 6, 2007 |  BC Extra  |  Financial News

MPM Capital closes $550 million fund

MPM Capital closed its MPM BioVentures IV at $550 million. MPM said 85% of the fund will be invested in biotech and specialty pharmaceuticals, with the remainder going to medtech, tools and diagnostics. MPM expects...
07:00 , Sep 25, 2006 |  BioCentury  |  Strategy

Midcap wake-up call

For years, it has been an open secret that many of Europe's family-owned mid-cap pharmas have been lost at sea, unable to adapt to the new world of innovative in-house R&D and aggressive in-licensing. Merck...
07:00 , Jun 19, 2006 |  BioCentury  |  Finance

Ebb & Flow

Investors gave a cool response to Intercell’s news that it had signed a deal covering its Japanese encephalitis vaccine with Novartis (NVS; SWX:NOVN). The agreement includes milestones up to E37 million ($46.7 million) split almost...
07:00 , May 8, 2006 |  BioCentury  |  Finance

U.S. investment in Europe

U.S. investment in Europe U.S. investment in Europe European venture rounds in excess of $30 million in the past year. Selected firms that do not list a major office in Europe are in boldface. Temasek...